Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Pharmaceutical Drug Import to Russia (May 2020)

Monday, June 29, 2020

Between January and May 2020, Russia imported 168.6 bln RUB worth of ready-made pharmaceuticals (customs clearance and VAT included), which is in monetary terms (rubles) 27% lower than in 2019, and 52.5 bln RUB worth of in-bulk drugs, which is 12% higher than in 2019.

May was the first month of 2020, when the dynamics of the import of ready-made pharmaceutical drugs in monetary terms were positive (+16%). While not a drastic change, that did make the total dynamics for the period between January and May considerably better. The dynamics in physical terms (units) are +19% for May but -38% for the first five months of 2020, with the import volume of 0.45 bln units. If calculated in minimum dosage units (MDU), the dynamics are -33%, and the import volume is 9 bln MDUs. The difference in dynamics can be explained by the fact that the number of MDUs in every retail package averaged 20.7 in 2020 against 19.3 in 2019.


Shire Pharmaceuticals and BioMarin Pharmaceuticals have the highest dynamics in monetary terms among the top 20 manufacturers of ready-made drugs (imports grown by 3.9 and 2.4 times, respectively). The import of Shire’ Elaprase has grown by 4.3 times, and in 2019 the company did not import Replagal and Vpriv (the import of both drugs amounted to 750 bln RUB this year). BioMarin has increased its import of Naglazim by 1.5 times, but Vimizim and Brineura, which had not been imported a year earlier, contributed to the dynamics the most.

Just like in April, Astellas and Eisai have the highest dynamics in monetary terms among the top 20 manufacturers of in-bulk drugs (imports grown by 5.2 and 3.2 times, respectively). Among the companies that did not import to Russia between January and May 2019, Geropharm is worth mentioning. In April 2020, Geropharm started importing nootropic Recognan (oral solution) from Italy. the company produces Recognan in the form of solution for injections at the facilities of Moscow Endocrine Plant. Mirpharm is another “new” manufacturer on the list. In January 2020, it started importing antimicrobial Miroful capsules. The drug in ready-made form is manufactured in Italy and packaged at OKhFK in Obninsk, Kaluga region.

Dynamics of import of pharmaceuticals to Russia (EEU countries excluded), free circulation prices including customs clearance and VAT, RUB (2016 – 2019, January – May 2020)